EBMT 2022 | autoHSCT in MCL in early vs late in the treatment regimen
Eleni Gavriilaki, MD, PhD, G Papanicolaou Hospital, Thessaloniki, Greece, shares the results of a study comparing the outcomes of patients with mantle cell lymphoma (MCL) who received an autologous hematopoietic stem cell transplant (autoHSCT) early versus late in their treatment. Overall, it was found that due to patient eligibility and stem cell mobilization, autoHSCT was performed more frequently in the late treatment period. In addition, it was found that patients who received an autoHSCT as consolidation therapy together with other novel agents used in the late treatment period had a better disease-free survival (DFS) and overall survival (OS). Further studies are required to refine MCL treatment and optimize patient outcomes. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Disclosures
Dr Gavriilaki has served as a consultant and/or received honoraria from Alexion Pharmaceuticals, Omeros Corporation, and Sanofi. Dr Gavriilaki has received research support from Jazz Pharmaceuticals.
